** Analysts at Jefferies are of the view that CSL Vifor will be impacted by Viatris possibly launching a generic Venofer (iron sucrose injection) in the U.S. market in second half of CY24
** Brokerage maintains CSL's price target of A$338.50/shr and "buy" rating
** Jefferies expects CSL Vifor to receive a lower distributor margin on sales of the active pharmaceutical ingredient for Venofer in the U.S. compared to the margin on sales of the product in the European Union
** Brokerage sees CSL's earnings per share declining by 0.8% in FY26
** 11 of 16 analysts rate the stock "buy" or higher, 4 "hold" and 1 rates "sell"; their median PT is A$310.00 – LSEG data
** Stock had fallen 1% this year, as of last close
(Reporting by Shivangi Lahiri in Bengaluru)
((shivangi.lahiri@thomsonreuters.com))
Comments